1 Stock Defying the Downturn to Buy, and 1 to Avoid
It isn't easy for corporations to perform well while the rest of the market tanks. Companies that managed to pull that off over the past year deserve some praise. But that alone isn't a good enough reason to buy their shares. Among those stocks that crushed the market, some will go on to provide market-beating returns over the long run, while others have less certain prospects.
Let's look at one company in each category: AstraZeneca (NASDAQ: AZN) and Biogen (NASDAQ: BIIB). Here is why the former is a solid buy, and why investors should hold off on the latter for now.
AstraZeneca is a U.K.-based pharmaceutical company with a long list of products, many of which are hugely successful and generate well over $1 billion in annual sales. The company's oncology lineup is particularly impressive, with products such as Tagrisso, Imfinzi, Lynparza, and Calquence, all of which are blockbusters.
Source Fool.com
